Fangzhou has signed a MoU with Novo Nordisk to collaborate on the management of serious chronic diseases, including obesity and diabetes.

A genetic test may one day predict a child’s risk of obesity in adulthood, paving the way for early interventions ...

As the global obesity medication market skyrockets, South Korean pharmaceuticals are rushing to develop national obesity drugs. Currently, the global industry is dominated by GLP-1 (glucagon-like ...

Novo Nordisk's recent financial results and clinical progress haven't impressed Wall Street. Investors looking to strike ...

Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, signed a Memorandum of ...

A recent spot check revealed that drugstores in Nairobi, including online pharmacies, are selling more insulin than in ...

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.